Monday, January 07, 2019
Locate Bio Ltd, a cell and gene therapy platform company developing a pipeline of regenerative medicine products, has received notification that it will be granted key patents covering its IntraStem technology in the United States and Europe (patent application numbers US20170080101A1 & EP3082871A1).
IntraStem is a cell penetrating peptide (CPP) based intracellular delivery system designed to overcome the limitations of current gene therapy vectors. It raises the efficacy bar for non-viral transfection systems whilst offering greater versatility, expected safety and lower manufacturing costs compared to viral vectors. As a next-generation approach, IntraStem is able to deliver a wide range of biologics including plasmid DNA, mRNA, siRNA, proteins and antibodies, with high efficiency in an array of cell types including many hard-to-transfect cells. Repeated or sustained administration is also possible with IntraStem due to its low toxicity profile, while good tissue penetration has been demonstrated following local delivery in vivo. These combined attributes make IntraStem an ideal technology for the transfection of cells or more generally the delivery of biologics into cells in vivo and therefore enable cellular reprogramming or gene editing directly in patients. Locate is currently evaluating new therapeutic applications for this exciting new technology.
Dr Nick Staples, Chief Executive of Locate commented: “The granting of our first IntraStemTM patents in the US and Europe adds to the excitement building around our next generation, non viral transfection technology. We are delighted with the comparative performance of IntraStem versus current transfection standards, which has now extended across a wide range of cell types, payloads and preclinical models. The broad utility of IntraStem opens up a multitude of therapeutic opportunities, including gene editing and cell reprogramming in vivo. We are presently evaluating new product opportunities in therapy areas where cell and gene therapies may deliver breakthrough and potentially curative benefits to patients”.
Locate’s CEO, Nick Staples and CSO, Professor Kevin Shakesheff are attending the Biotech Showcase at JPM 2019 in San Francisco through to 9th January should you wish to meet with the company.
Intellectual Property
Locate Bio Ltd United States Patent and Trademark Office European Patent Office
Europe > Germany
Europe > United Kingdom
North America > United States of America
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
These cookies are needed for adding comments on this website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com